Skip to content

Fibromyalgia TENS in Physical Therapy Study (TIPS): an Embedded Pragmatic Clinical Trial

Fibromyalgia TENS in Physical Therapy Study (TIPS): an Embedded Pragmatic Clinical Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04683042
Enrollment
459
Registered
2020-12-24
Start date
2021-01-22
Completion date
2025-03-11
Last updated
2025-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

Transcutaneous Electrical Nerve Stimulation (TENS), chronic pain, fibromyalgia, movement pain

Brief summary

The purpose of this study is to determine if addition of Transcutaneous Electrical Nerve Stimulation (TENS) to routine physical therapy improves movement-evoked pain in patients with fibromyalgia (FM). The study will also determine if addition of TENS to routine physical therapy (PT) improves disease activity and symptoms, increases adherence to physical therapy, increases the likelihood of meeting patient specific functional goals, and reduces medication use.

Detailed description

This study is a pragmatic clinical trial in outpatient PT practices utilizing cluster randomization by healthcare system and facility size. Sites will be randomized to enroll all eligible and consented participants with FM to TENS with PT, or PT only (no TENS). We are identifying 25-35 clinics across 6 healthcare systems in both rural and urban settings. We will enroll 450 patients that self report a clinician diagnosis of FM. At each site, TENS (or no TENS) will be applied during each visit along with individualized PT treatment specified by the physical therapist. Participants randomized to TENS intervention sites will receive TENS units and electrodes at baseline to be applied to the cervical and lumbar regions. Participants will take the units home and bring the units back to their PT clinic visits with instructions for use at home while active and during their exercises. The physical therapist at each clinic will complete routine documentation of treatment. In addition to the primary and secondary outcomes, Electronic Health Record data variables will be collected as exploratory outcomes. Variables including adherence to treatment will be extracted from each site's Electronic Health Record. Patient-reported assessments will be obtained from the participant's at home the day of their second PT visit (Baseline) and at 30, 60 (primary outcome), 90, and 180 days following enrollment. The primary and secondary outcome assessments will be comparing TENS and no TENS groups in terms of changes from baseline to 60 days. Participants will be identified after they are referred for PT for treatment of primary fibromyalgia (FM) or chronic pain (pain lasting more than three months). At their first (intake) physical therapy visit, they will be provided information about the study that can be accessed on paper or on-line. They will perform an electronic screening form on the first visit if interested in participating. Participants will provide e-consent after eligibility is confirmed at the initial PT visit. At the second PT visit after e-consent is signed, participants will be provided instructions on logging onto REDCap for data capture and accessing the case report forms. Participants enrolled at a TENS site will then be instructed in use of TENS and the TENS unit with electrodes will be provided. Those participants enrolled at a no TENS site will skip the instruction in use of TENS but will then receive instructions along with the TENS units at day 65. Participants will be instructed to capture all baseline assessments at home before their next PT visit before and following their first TENS treatment (or no TENS) at home (day 1). At 30, 60, 90, and 180 days following enrollment, participants will complete the same assessments at home including pain ratings at rest and with movement along with questionnaires. The primary and secondary outcome assessments will be comparing TENS and no TENS groups in terms of changes from baseline to 60 days.

Interventions

DEVICETranscutaneous Electrical Nerve Stimulation (TENS) with PT

Use of TENS units along with routine PT therapy

OTHERPT only

Routine PT therapy only

Sponsors

Kathleen Sluka
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This study is a pragmatic clinical trial in outpatient PT practices utilizing cluster randomization by facility and facility size. Sites will be randomized to enroll all eligible and consented participants with FM to TENS with PT, or PT only (no TENS). We have identified 25-35 clinics across 6 healthcare systems in both rural and urban settings.

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18 until 99. 2. Clinician diagnosis of FM 3. Referred for land-based PT 4. Referred for treatment for FM or chronic pain (pain lasting more than 3 months) 5. Able to provide informed consent. 6. Fluent in reading English 7. Willing to use TENS

Exclusion criteria

1. Contraindications to TENS use including: 1. Pacemaker, defibrillator, implanted neurostimulator or implanted device 2. Epilepsy 3. Currently pregnant or plan to become pregnant in the next 6 months 4. Allergic reaction to patches with gel 5. Current treatment for cancer 2. Currently enrolled in another pain control study 3. Use of TENS within the last 30 days 4. Clinically unstable medical or psychiatric issues

Design outcomes

Primary

MeasureTime frameDescription
Reduction of movement-evoked pain (0-10 Low to High scale) during the Sit and Stand TestResearch Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days HomeNumeric rating scale of 0-10 for reduction of movement-evoked pain measured by 11-point NRS from baseline to 60 days.

Secondary

MeasureTime frameDescription
Pain interference (BPI) (0-10 Low to High Scale)Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home11 items measuring pain severity and interference with daily activities on a 0-10 scale.
FM Disease activity (FIQR) (0-10 Low to High Scale)Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home21 items used to evaluate function, overall impact, and symptoms in patients with fibromyalgia.
Resting fatigue (NRS) (0-10 Low to High Scale)Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days HomeThe severity of fatigue will be measured with a 0 to 10 scale where 0 is no fatigue and 10 is worst fatigue imaginable.
Change in the resting pain score (0 - 10 Low to High scale)Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days HomeThe severity of pain will be measured on a 0 to 10 numeric rating scale where 0 is no-pain and 10 is worst pain imaginable.
Multidimensional assessment of fatigue (MAF) (0-10 Low to High Scale)Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home16 items measuring fatigue according to four dimensions: degree and severity, distress that it causes, timing of fatigue, and impact on various activities of daily living.
Rapid assessment of physical activity (RAPA) (0-10 Low to High Scale)Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days Home9 items evaluating current level of physical activity.
Patient global impression of change (PGIC) (0-6 Scale)Day 60 +/- 5 days HomeEvaluates overall health status as perceived by the patient in a seven-point single-item scale ranging from 'very much worse' to 'very much improved'
Movement-evoked fatigue (NRS) (0-10 Low to High Scale)Research Homework before PT Visit 3 (Day 1), Day 60 +/- 5 days HomeFatigue during a five times sit and stand test will be measured with a 0 to 10 numeric rating scale with 0 as no fatigue and 10 as the worst fatigue imaginable.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026